ADAP - TCR2 Therapeutics Files Terms For U.S. IPO
Quick Take
TCR2 Therapeutics (TCRR) intends to raise gross proceeds of $75 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is developing therapies that harness the patient's immune system to fight cancer irrespective of human leukocyte antigens [HLA] subtype or presence.
TCRR is an ultra-early-stage biopharma seeking funding for Phase 1/2 trials for its lead candidate.
Company & Technology
Cambridge, Massachusetts-based TCR2 Therapeutics was founded in 2015 to develop T-cell immunotherapies that target tumors irrespective of HLA subtype or presence.
Management is headed by President, CEO and